What Actually Happened

On June 9, 2025, Jan Janisch-Hanzlik — a 49-year-old nurse from Blair, Nebraska — sat down at the University of Nebraska Medical Center in Omaha and became the first patient enrolled in a CAR T-cell trial for multiple sclerosis at that institution. She had called the clinic every other month until they let her in. That's how desperate things had gotten.

Her MS had already forced her out of active nursing. Frequent falls meant she was afraid to hold her own grandchildren. A wheelchair was looking less like a possibility and more like an inevitability.

She knew the risks — dangerous inflammation, potential brain swelling, side effects that can affect speech and movement. She took the shot anyway.

What CAR T Actually Is

CAR T — Chimeric Antigen Receptor T-cell therapy — takes your own immune cells, reprograms them in a lab to hunt a specific target, and puts them back in your body. Think of it as biological software update meets guided missile.

The FDA first approved it in 2017 for an aggressive form of leukemia. According to New Scientist, it has since produced results in blood cancers that no other treatment could match — curing patients when everything else had failed.

The problem for cancer: it only works on blood cancers, NOT solid tumors. And the side effects can be serious.

Autoimmune diseases and blood cancers share something fundamental. Both involve rogue cells that refuse to die when they should. A study published earlier this year confirmed what researchers first suspected in the 1950s — that rogue immune cells in autoimmune disease carry mutations in the genes that govern self-destruction. They just keep attacking. According to Reuben Benjamin at King's College London, speaking to New Scientist, this makes autoimmune conditions "even more similar to cancers than we thought."

That similarity is exactly why researchers started asking: what if CAR T could hunt down these rogue cells the same way it hunts cancer?

The Cases That Are Turning Heads

So far, the answer appears to be yes.

Fabian Müller — a hematologist-oncologist at the University Hospital of Erlangen, Germany — described to The Atlantic one of the most extreme cases yet treated. A 47-year-old mother of two had three simultaneous severe autoimmune diseases attacking her blood. Her care team made nine separate attempts to treat her. All failed. By early 2025 she had been hospitalized in Dresden for over two months straight, receiving up to three blood transfusions per day.

She received CAR T early last year. She hasn't needed a hospital stay in months. She's back to a mostly normal life.

Nine failed treatments. Constant transfusions. Now: no hospital stays, no crisis management, near-normal life.

Some patients in early trials are now years out from a single CAR T treatment — no drugs, no relapse, sustained remission. According to The Atlantic, Müller and his colleagues are cautious but increasingly willing to say the word "permanent."

How Big Is This Pipeline?

Big. According to New Scientist, "all the big pharma companies are jumping on the bandwagon now." Hundreds of clinical trials are currently active across conditions including MS, lupus, Graves' disease, vasculitis, rheumatoid arthritis, systemic sclerosis, and type 1 diabetes.

Benjamin told New Scientist that first approvals could come as early as next year, with results showing CAR T is "vastly superior" to current treatments.

At Roswell Park Comprehensive Cancer Center in Buffalo, rheumatologist Dr. Alicia Lieberman is leading trials targeting lupus, lupus nephritis, systemic sclerosis, and MS. Her collaborator Dr. Shernan Holtan — Chief of Blood and Marrow Transplant at Roswell Park — put the long-term goal plainly: "People don't need medications for the rest of their lives and could potentially be cured."

The National Institutes of Health estimates nearly 1 in 10 Americans lives with an autoimmune disease. That's roughly 33 million people — many of them managing symptoms for life, on expensive medications, with no end in sight.

What the Coverage Is Missing

Most mainstream coverage frames this as a feel-good medical miracle story and moves on. A few things deserve harder scrutiny.

Cost. CAR T cancer treatments currently run $400,000 to $500,000 per infusion. That number isn't prominently featured in any of the source reports covering this autoimmune breakthrough. If this therapy follows the same pricing model, "one-and-done" could mean one catastrophically expensive treatment that most Americans can't afford without insurance coverage battles that last longer than the hospitalization itself. Nobody is talking about this loudly enough.

Long-term unknowns. The therapy was first trialed on an autoimmune patient in 2021. That's four years of data — not enough to call anything definitive. Müller and other researchers say openly they don't yet know how long remission lasts or what side effects might emerge over decades. The science is promising. It is NOT settled.

Manufacturing scale. CAR T is a personalized therapy — it's made from YOUR cells. That's not like manufacturing a pill. Scaling this to serve millions of autoimmune patients is an industrial and logistical challenge nobody in mainstream coverage is seriously engaging with yet.

What This Means for Regular People

If you or someone you know has MS, lupus, rheumatoid arthritis, or another autoimmune disease — pay attention. Clinical trials are open now. Roswell Park, the University of Nebraska, and the University Hospital of Erlangen are among the centers actively enrolling patients.

This is NOT a guaranteed cure. It is NOT ready for mass deployment. The risks are real — serious inflammation, potential neurological side effects, the full weight of an immune system being dramatically reprogrammed.

But for people who've exhausted every other option, like Janisch-Hanzlik calling a clinic every two months until they let her in, this may be the most significant development in autoimmune medicine in their lifetime.

The science says these rogue cells can be hunted down and destroyed. Whether the medical system — and its pricing structures — will let that science actually reach patients remains to be seen.